Mats-Olof Wallin

Directeur Financier/CFO chez OxThera AB

73 ans

Health Technology

Consumer Services

Postes actifs de Mats-Olof Wallin

Sociétés	Poste	Début	Fin
OxThera AB OxThera AB Pharmaceuticals: GenericHealth Technology OxThera AB develops pharmaceutical products for treatment of hyperoxaluria. Its intellectual property includes worldwide patents for compositions and treatment of hyperoxaluria with bacteria and enzymes. The firm?s products in pipeline include Oxabact, for the treatment of primary hyperoxaluria and oxazyme for the prevention of oxalate malabsorption and recurring kidney stones in secondary hyperoxaluria. The company was founded in 2005 and is headquartered in Stockholm, Sweden.	Directeur Financier/CFO	01/01/2020	-

Sociétés	Poste	Début	Fin
KARO PHARMA AB (PUBL)	Directeur Financier/CFO	01/01/2018	01/10/2019
SWEDISH ORPHAN BIOVITRUM AB	Directeur Financier/CFO	08/04/2013	20/07/2018
BIOTAGE AB	Directeur Financier/CFO	17/05/2010	01/01/2012
BIOTAGE AB	Public Communications Contact	17/05/2010	01/01/2012

University of Uppsala

Undergraduate Degree

Internationale

Suède

Opérationnelle

Director of Finance/CFO	4
Public Communications Contact	1
Undergraduate Degree	1

Sectorielle

Health Technology	5
Consumer Services	2

Fonctions occupées

Actives

Inactives

Sociétés cotées

Entreprise privées

Entreprise privées	1
OxThera AB OxThera AB Pharmaceuticals: GenericHealth Technology OxThera AB develops pharmaceutical products for treatment of hyperoxaluria. Its intellectual property includes worldwide patents for compositions and treatment of hyperoxaluria with bacteria and enzymes. The firm?s products in pipeline include Oxabact, for the treatment of primary hyperoxaluria and oxazyme for the prevention of oxalate malabsorption and recurring kidney stones in secondary hyperoxaluria. The company was founded in 2005 and is headquartered in Stockholm, Sweden.	Health Technology

Entreprise privées

Health Technology